Wide Ranks

BYSI

BeyondSpring, Inc.

1.89

Top Statistics
Market Cap 76 M Forward PE -4.02 Revenue Growth 14.30 %
Current Ratio 1.82 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -4.15 Enterprise / Revenue 37.00 Price To Sales Trailing12 Months 40.60
Profitability
Profit Margins 0.00 % Operating Margins -742.20 %
Balance Sheet
Total Cash 14 M Total Cash Per Share 0.3560 Total Debt 3 M
Total Debt To Equity Current Ratio 1.82 Book Value Per Share -0.7490
All Measures
Short Ratio 8907.00 % Message Board Id finmb_409784135 Shares Short Prior Month 2 M
City Florham Park Uuid 13bae88f-b6da-35bd-a612-d48b2fa6eb85 Previous Close 1.85
First Trade Date Epoch Utc 1 B Book Value -0.7490 Beta 0.2990
Total Debt 3 M Volume 40449 Fifty Two Week Low 0.7780
Total Cash Per Share 0.3560 Total Revenue 1 M Shares Short Previous Month Date 1 B
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -742.20 %
Net Income To Common -15568000 Short Percent Of Float 0.0829 Implied Shares Outstanding 40 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 28990
Average Volume10days 28990 Total Cash 14 M Next Fiscal Year End 1 B
Revenue Per Share 0.0480 Held Percent Insiders 0.2554 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 1.85
Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.13
Open 1.92 Dividend Yield 0.00 % State NJ
Return On Assets -0.3964 Time Zone Short Name EST Trailing Eps -0.4000
Day Low 1.67 Address1 100 Campus Drive Shares Outstanding 40 M
Price Hint 4 Target High Price 0.0000 Website https://beyondspringpharma.com
52 Week Change 1.21 Average Volume 25004 Forward Eps -0.4700
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 175.40 %
Is_sp_500 False Regular Market Day High 2.28 Profit Margins 0.00 %
Fifty Two Week High 4.00 Day High 2.28 Shares Short 2 M
Regular Market Open 1.92 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 37.00 Revenue Growth 14.30 % Shares Percent Shares Out 0.0516
Currency USD Time Zone Full Name America/New_York Market Cap 76 M
Is_nasdaq_100 False Zip 07932 Quote Type EQUITY
Industry Biotechnology Long Name BeyondSpring Inc. Regular Market Day Low 1.67
Held Percent Institutions 0.1379 Current Price 1.89 Address2 4th Floor, Suite 410 West Side
Enterprise To Ebitda -4.15 Financial Currency USD Current Ratio 1.82
Gross Margins 100.00 % Industry Disp Biotechnology Country United States
Float Shares 25 M Two Hundred Day Average 2.26 Enterprise Value 69 M
Price To Sales Trailing12 Months 40.60 Forward PE -4.02 Regular Market Volume 40449
Ebitda -16715000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.

The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia.

It is also developing Plinabulin in combination with docetaxel vs.

docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type.

In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer.

Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration.

The company was founded in 2010 and is headquartered in Florham Park, New Jersey.